Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection
- PMID: 35740243
- PMCID: PMC9220332
- DOI: 10.3390/biomedicines10061224
Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection
Abstract
Current treatment for chronic HBV infection is mainly based on nucleos(t)ide analogues, that in most cases need to be administered for a patient's lifetime. There is therefore a pressing need to develop new therapeutic strategies to shorten antiviral treatments. A severe dysfunction of virus-specific T cell responses contributes to virus persistence; hence, immune-modulation to reconstitute an efficient host antiviral response is considered a potential approach for HBV cure. In this perspective, a detailed understanding of the different causes of T cell exhaustion is essential for the design of successful functional T cell correction strategies. Among many different mechanisms which are widely believed to play a role in T cell dysfunction, persistent T cell exposure to high antigen burden, in particular HBsAg, is expected to influence T cell differentiation and function. Definitive evidence of the possibility to improve anti-viral T cell functions by antigen decline is, however, still lacking. This review aims at recapitulating what we have learned so far on the complex T cell-viral antigen interplay in chronic HBV infection.
Keywords: HBsAg; T cells; antigen load; chronic HBV infection.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.Gastroenterology. 2012 Oct;143(4):963-73.e9. doi: 10.1053/j.gastro.2012.07.014. Epub 2012 Jul 14. Gastroenterology. 2012. PMID: 22796241
-
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.Clin Gastroenterol Hepatol. 2013 Aug;11(8):1004-10.e1. doi: 10.1016/j.cgh.2013.01.026. Epub 2013 Feb 1. Clin Gastroenterol Hepatol. 2013. PMID: 23376799
-
A novel orally available small molecule that inhibits hepatitis B virus expression.J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25. J Hepatol. 2018. PMID: 29079285
-
Aiming for cure in HBV and HDV infection.J Hepatol. 2016 Oct;65(4):835-848. doi: 10.1016/j.jhep.2016.05.043. Epub 2016 Jun 3. J Hepatol. 2016. PMID: 27270043 Review.
-
Latest developments in the treatment of hepatitis B.Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8. Minerva Gastroenterol Dietol. 2016. PMID: 26448309 Review.
Cited by
-
What will it take to cure hepatitis B?Hepatol Commun. 2023 Mar 24;7(4):e0084. doi: 10.1097/HC9.0000000000000084. eCollection 2023 Apr 1. Hepatol Commun. 2023. PMID: 36972391 Free PMC article.
-
HBsAg level defines different clinical phenotypes of HBeAg(-) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality.Front Immunol. 2024 Mar 13;15:1352929. doi: 10.3389/fimmu.2024.1352929. eCollection 2024. Front Immunol. 2024. PMID: 38545116 Free PMC article.
References
-
- Fisicaro P., Barili V., Rossi M., Montali I., Vecchi A., Acerbi G., Laccabue D., Zecca A., Penna A., Missale G., et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front. Immunol. 2020;11:849. doi: 10.3389/fimmu.2020.00849. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources